The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.
Dose escalation to the prostate improves tumor control but at the expense of increased rectal toxicity. Modern imaging can be used to detect the most common site of recurrence, the intraprostatic lesion (IPL), which has led to the concept of focusing dose escalation to the IPL in order to improve the therapeutic ratio. Imaging must be able to detect lesions with adequate sensitivity and specificity to accurately delineate the IPL. This information must be carefully integrated into the radiotherapy planning process to ensure the dose is targeted to the IPL. This review will consider the role and challenges of multiparametric MRI and PET computed tomography in delineating a tumor boost to be delivered by external beam radiotherapy.
The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Angela U
AU
Pathmanathan
The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SM2 5PT, UK.
Emma J
EJ
Alexander
The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Robert A
RA
Huddart
The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SM2 5PT, UK.
Alison C
AC
Tree
D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D064847:Multimodal Imaging / Q000379:methods / Q000592:standards; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D015203:Reproducibility of Results
MRI; PET-CT; boost; dose escalation; intraprostatic lesion; prostate cancer